62655-20-3 Usage
Uses
Used in Pharmaceutical Industry:
1,3-Dibromo-5-isopropylbenzene is used as a synthetic intermediate for the production of pharmaceuticals, contributing to the development of new drugs and medicines. Its unique chemical structure allows for the creation of a wide range of therapeutic agents.
Used in Pesticide Industry:
In the pesticide industry, 1,3-Dibromo-5-isopropylbenzene is utilized as a key intermediate in the synthesis of various pesticides, helping to develop effective solutions for pest control and crop protection.
Used in Organic Chemical Reactions:
1,3-Dibromo-5-isopropylbenzene is employed as a reagent in organic chemical reactions, facilitating the synthesis of complex organic molecules and contributing to advancements in organic chemistry.
Safety Considerations:
Due to its hazardous nature, 1,3-Dibromo-5-isopropylbenzene is harmful if swallowed, inhaled, or absorbed through the skin, and may cause irritation to the eyes, skin, and respiratory system. It is crucial to handle and store 1,3-DIBROMO-5-ISOPROPYLBENZENE with care, adhering to appropriate safety protocols to minimize the risk of exposure.
Check Digit Verification of cas no
The CAS Registry Mumber 62655-20-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,6,5 and 5 respectively; the second part has 2 digits, 2 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 62655-20:
(7*6)+(6*2)+(5*6)+(4*5)+(3*5)+(2*2)+(1*0)=123
123 % 10 = 3
So 62655-20-3 is a valid CAS Registry Number.
62655-20-3Relevant academic research and scientific papers
A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790Mmutant with improved pharmacokinetic properties
Yu, Lei,Huang, Minhao,Xu, Tianfeng,Tong, Linjiang,Yan, Xiao-e,Zhang, Zhang,Xu, Yong,Yun, Caihong,Xie, Hua,Ding, Ke,Lu, Xiaoyun
, p. 1107 - 1117 (2016/12/30)
Structural optimization of pyrido[2,3-d]pyrimidin-7-ones was conducted to yield a series of new selective EGFRT790Minhibitors with improved pharmacokinetic properties. One of the most promising compound 9s potently suppressed EGFRL858R/T790Mkinase and inhibited the proliferation of H1975?cells with IC50values of 2.0?nM and 40?nM, respectively. The compound dose-dependently induced reduction of the phosphorylation of EGFR and downstream activation of ERK in NCI[sbnd]H1975?cells. It also exhibited moderate plasma exposure after oral administration and an oral bioavailability value of 16%. Compound 9s may serve as a promising lead compound for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.
